Navigation Links
St. Jude creates $5.5 million endowment for cancer research to be held by the hospital CEO
Date:8/2/2013

St. Jude Children's Research Hospital has earmarked $5.5 million for the creation of the Donald Pinkel Endowed Chair of Pediatric Cancer Treatment, which has been granted by the ALSAC and St. Jude Boards of Directors and Governors.

The endowment, among the largest of its kind in the country, honors the hospital's first director and will be held by the sitting St. Jude CEO. Dr. William E. Evans, the present St. Jude director and CEO, is its first designee. The endowment provides support for the CEO's research and academic programs.

"This endowment illustrates the importance of research being pursued from all levels at St. Jude," Evans said. "All St. Jude CEOs have remained actively engaged in research to discover, innovate and advance cure rates."

Evans' work focuses on better understanding the genomic basis of childhood cancers and developing individualized approaches to cancer treatment. This involves the translation of pharmacogenomic discoveries into personalized treatments for pediatric cancers.

Evans said that St. Jude owes its institutional focus and relentless spirit to Pinkel. A medical doctor, Pinkel challenged the standard 1960s treatment for childhood cancer with significant results.

Despite often-strident disagreement from many in the scientific and medical community, Pinkel developed an unconventional approach to treating acute lymphoblastic leukemia (ALL), the most common pediatric cancer. His revolutionary Total Therapy regimen, which he divided into a series of studies, combined multiple anticancer drugs with radiation treatment.

At a time when survival was estimated at 4 percent, the Total Therapy approach achieved a 50 percent survival rate and drove important improvements in treating both childhood and adult cancers. Total Therapy also served as the foundation for future St. Jude innovations and contributions to cancer research and treatment. Among them has been a steady increase in ALL survival, with St. Jude having the highest published survival rate for ALL at 94 percent.

Ensuring survival was the key for early childhood cancer research, and that meant highly aggressive therapy. Evans' research provides critical advances in the next revolution for cancer treatmentfinding the right treatment based on individual indicators, and providing only the amount of treatment necessary for success, minimizing side effects and potential later health impacts from treatment. For example, by better understanding how drugs interact with patients individually and by employing more sophisticated monitoring, clinicians have been able to discontinue the use of cranial irradiation in treatment of the disease, thus sparing children from many common side effects.

"I am deeply honored to be named the first Donald Pinkel Endowed Chair," Evans said. "When I first came to St. Jude in 1972 as a student, Dr. Pinkel was the director, and he was a person whom everyone looked up to, largely because he did not expect more out of others than he expected from himself. He led by example. I respected him because of what he had already accomplished, and because he was interested in hearing everyone's ideas, even those of a student like me."


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. NJIT designer creates an ergonomic chair for musicians
2. 'EMT Exam Ace' Creates Free EMT Resources Page
3. Mayo Clinic YES Board creates efficiencies in emergency rooms
4. Police officer stress creates significant health risks, study finds
5. Mayo Clinic creates tool to track real-time chemical changes in brain
6. Team creates new view of bodys infection response
7. A CNIO team creates a unique mouse model for the study of aplastic anaemia
8. Scientist creates new cancer drug that is 10 times more potent
9. Autism Speaks creates Delivering Scientific Innovation for Autism LLC
10. Long Island Trainer Sylvia Nasser Creates New Weight Loss and Fitness Program for the Modern Woman
11. Unique Web Consulting Creates a New Website for Olive Dental Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: